Molecular diagnosis and site-specific therapy in cancer of unknown primary: an important milestone

Lancet Oncol. 2024 Aug;25(8):955-956. doi: 10.1016/S1470-2045(24)00344-9. Epub 2024 Jul 25.

Authors

F Anthony Greco¹, Chris Labaki², Elie Rassy³

Affiliations

¹ Sarah Cannon Research Institute and Cancer Center, Tennessee Oncology, Nashville, TN 37203, USA. Electronic address: fgreco@thonc.com.
² Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
³ Department of Medical Oncology, Gustave Roussy Institut, Villejuif, France.

PMID: 39068942
DOI: 10.1016/S1470-2045(24)00344-9

No abstract available

MeSH terms

Biomarkers, Tumor / genetics
Humans
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Neoplasms, Unknown Primary* / diagnosis
Neoplasms, Unknown Primary* / genetics
Neoplasms, Unknown Primary* / pathology
Neoplasms, Unknown Primary* / therapy
Precision Medicine

Substances

Biomarkers, Tumor